If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.
|
Tumour Group / Site |
Trial Title |
Opening Date |
|---|
| BREAST | A Randomized Trial of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer CCTG MA.39 | Sept 2019
|
BREAST
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of GDC-0077 Plus Palbociclib And Fulvestrant Versus Placebo Plus Palbociclib And Fulvestrant In Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer (WO41554) PIK3
| July 2020
|
GU
| A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients with Advanced Prostate Cancer Post Abiraterone
(PROTRACT)
| Dec
2020
|
Lung
| EA5163/S1709 INSIGNA: A Randomized, Phase III Study of First line Immunotherapy alone or in Combination with Chemotherapy in Induction / Maintenance or Post-progression in Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis CCTG BRC.7
| July 2020
|
|
Lymphoma | Biology of Lymphoid Cancer
Lymphoid Study | Jan 2014 |
| Melanoma | A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma CCTG ME.13 | July 2017
|
STOP
| Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancers (The STOP Trial): A Randomized Phase II Trial
| May 2020
|
